NEW YORK, May 11 - Merck's $620 million acquisition of Rosetta will bring all of Rosetta's research and development efforts under the control of Merck's management, but won't affect Rosetta's Resolver business, a Rosetta spokeswoman told GenomeWeb.
Registering provides access to this and other free content.
Already have an account?Login Now.
The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.
A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.
The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.
In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.